With over 100,000 patients with gastric conditions across our global network of 3,600 sites, we are committed to the growing health concern and support of biopharmaceutical studies for gastrointestinal disorders. This has resulted in approximately 80 active clinical gastrointestinal studies being conducted via the assessment of more than 18,500 patients.
Areas of expertise include
Patients
7,709
randomised
Studies
286
performed
Dr Radoslaw Janiak
Chief Operating Officer, Site Solutions
Specialist service offerings
The IBDconnect solution
The IBDconnect solution involves our partnering with the GI practice. We’ll work closely with the GI and their team to provide patients with broader access to clinical studies that might otherwise not be available to them.
We have the track record of success, turn-key infrastructure, clinical research experts, and capacity to implement such a solution to the high-demand arena of IBD trials.
India, a new source of patients
Our whitepaper demonstrates that the Indian market is emerging as an ideal source for Inflammatory Bowel Disease (IBD) patients. The network contains 57 high quality sites, including 12 that specialise in gastroenterology. Our local partner, S4 India, has in-depth country-specific knowledge and a pool of 400+ experienced and highly qualified investigators.
Together, AES and S4 can pave the way with all-inclusive guidance through study conduct, high-quality data, rapid start-up and streamlined processes.
Downloads
Connecting GI practices and their IBD patients to clinical research.
Bringing studies to IBD patients and their physicians.
Paving the way to successful clinical research in India.
Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are creating widespread concern in the medical profession due to a low diagnosis rate and lack of approved therapies.
We have been seeking out new tools and strategies to more efficiently recruit patients for these trials. We have access to a large pool of patients with co-morbidities such as obesity, Type 2 diabetes or other cardiovascular disease risk factors, which are known to be at a greater risk for NASH.
Working together on a focused approach ensures we can get the first patient to join the NAFLD/NASH study in the shortest time possible. We are not only recruiting patients, but also retaining them and increasing their motivation to participate in the right trial, which then enhances the overall quality of trial delivery.
Downloads
Our community of over 100 million patients includes thousands of identified patients with NAFLD, as well as those at high risk for NAFLD / NASH.